Efficacy and preclinical safety of ARB202, a potential first-in-class ...
2021年1月22日 · The present study aims to develop a humanized CDH17-CD3 bispecific T-cell engager antibody, ARB202, to treat advanced pancreatic and metastatic colon cancers. …
Phase 1A, first-in-human study of ARB202, bispecific antibody to …
2023年8月3日 · A bispecific T-cell engager ARB202 using CD3 to aid the formation of an immunological synapse CDH17 tumor cells and T-cells is being studied. Methods: In an …
ASCO突破峰会|针对新型胃肠癌靶点CDH17的双抗ARB 202公布最 …
2023年8月5日 · arb 202是基于arbele公司的专利技术开发的cdh17/cd3双抗，既能靶向胃肠道肿瘤的cd17，也能靶向t细胞上的cd3。arb 202对cdh17和cd3独特的差异结合亲和力使其具有高特 …
肝肠钙粘蛋白CDH17：单抗、双抗、CAR T“多管齐下”，胃肠道 …
2023年3月27日 · 此外，香港生物制药公司arbele的cdh17单抗（arb102）和双特异性抗体cdh17/cd3（arb202），正处于临床前研究阶段，用于治疗胰腺癌、胆管癌等实体瘤。另有研 …
Novel T-cell engager, CDH17 x CD3 cabotamig (ARB202
ARB202 is a first-in-class bispecific antibody based on Arbele's patented CDH17 biomarker. It targets both CDH17 on GI cancer as well as CD3 on T cells. The unique differential binding …
ArbeleBio
2024年8月2日 · ARB202 is a first-in-class bispecific antibody based on Arbele's patented CDH17 biomarker. It targets both CDH17 on GI cancer as well as CD3 on T cells. The unique …
Novel T-cell engager, CDH17 X CD3 cabotamig (ARB202) …
2024年4月26日 · ARB202 is a first-in-class bispecific antibody based on Arbele's patented CDH17 biomarker. It targets both CDH17 on GI cancer as well as CD3 on T cells. The unique …
Pharmacologic studies of CDH17/CD3 bispecific antibodies to …
2019年10月15日 · Results: One lead antibody, ARB202 exhibited high-affinity binding to CDH17 and CD3. In the presence of CDH17-positive pancreatic cancer cells, ARB202 stimulated in …
ARB-201 (ARB-201) - 药物靶点：CD3 x CDH17_在研适应症：结肠 …
ARB-201: 一种CD3刺激剂、CDH17拮抗剂药物，由Arbele Corp. (Arbele Corp.)公司最早进行研发，目前全球最高研发状态为临床前，作用机制: CD3刺激剂(T细胞表面糖蛋白CD3复合体刺激 …
艾贝乐公布ARB 202最新临床数据
2023年8月7日 · 8月2日，专注于胃肠癌症的生物医药科技公司香港艾贝乐在ASCO突破性会议上，公布了其首款CDH17xCD3双特异性T细胞参与抗体ARB 202的早期安全性数据。 1a期研究 …